Skip to main content
. Author manuscript; available in PMC: 2013 Oct 15.
Published in final edited form as: Cancer Res. 2012 Aug 20;72(20):5209–5218. doi: 10.1158/0008-5472.CAN-12-1187

Figure 6.

Figure 6

Failure to increase accumulation of pmel-1 T cells to tumor sites by anti-PD-1 in mice with IFN-γ receptor deficient or CXCL10 deficient in BM-derived cells receiving ACT therapy. BM chimera mice (N=3 for each group) were challenged with MC38/gp100 tumor and transferred with luciferase expressing pmel-1 T cells. Mice were intraperitoneally injected with 250μg either control antibody or anti-PD-1 Ab on days 0, 2 and 4 after T cell transfer. In vivo luciferase imaging was performed on day 6 after T cell transfer. Intensities of the luciferase signal at tumor sites in all tumor-bearing mice are depicted .